Distribuzione geografica
Continente #
EU - Europa 26018
NA - Nord America 2458
AS - Asia 235
SA - Sud America 2
AF - Africa 1
OC - Oceania 1
Totale 28715
Nazione #
IT - Italia 25278
US - Stati Uniti d'America 2443
UA - Ucraina 270
CN - Cina 215
SE - Svezia 193
DE - Germania 78
GB - Regno Unito 66
FI - Finlandia 59
FR - Francia 26
BE - Belgio 20
CA - Canada 15
NL - Olanda 7
RU - Federazione Russa 6
ES - Italia 5
IN - India 5
KR - Corea 5
JP - Giappone 4
IE - Irlanda 2
IR - Iran 2
PT - Portogallo 2
RO - Romania 2
SG - Singapore 2
AR - Argentina 1
AU - Australia 1
BG - Bulgaria 1
CH - Svizzera 1
EC - Ecuador 1
GR - Grecia 1
HK - Hong Kong 1
KZ - Kazakistan 1
MU - Mauritius 1
PL - Polonia 1
Totale 28715
Città #
Cagliari 25137
Fairfield 407
Woodbridge 265
Chandler 231
Houston 199
Nyköping 181
Seattle 171
Wilmington 153
Ashburn 152
Jacksonville 152
Cambridge 151
Ann Arbor 149
Dearborn 64
Nanjing 49
Boston 45
Beijing 34
Guangzhou 23
San Diego 22
Brussels 20
Changsha 18
Helsinki 17
Shenyang 15
London 14
Toronto 14
Nanchang 12
Rome 10
Milan 9
Redwood City 9
Tianjin 9
Jiaxing 8
Norwalk 8
Jinan 7
Orange 7
San Mateo 7
Auburn Hills 6
Boardman 6
Kunming 6
Verona 6
Brandizzo 5
Hangzhou 5
Hebei 5
Hefei 5
Los Angeles 5
Sassari 5
Augusta 4
Mountain View 4
Somma Vesuviana 4
Torino 4
Amsterdam 3
Chicago 3
Detroit 3
Islington 3
Leawood 3
Monmouth Junction 3
Ningbo 3
Barcelona 2
Costa Mesa 2
Dublin 2
Fuzhou 2
Harbin 2
Manitou Springs 2
Muenster 2
Redmond 2
Singapore 2
Sobrado de Paiva 2
Tonara 2
Valencia 2
Xian 2
York 2
Zhengzhou 2
Almaty 1
Arcevia 1
Ardabil 1
Buenos Aires 1
Calasetta 1
Camaiore 1
Catania 1
Cedar Knolls 1
Central District 1
Chongqing 1
Formia 1
Frankfurt am Main 1
Frontone 1
Fulda 1
Gravina di Catania 1
Indiana 1
Jaipur 1
Ladispoli 1
Madrid 1
Millbury 1
Mumbai 1
Pavia 1
Polska 1
Qingdao 1
Quevedo 1
Rhodes 1
Rockville 1
Rovato 1
Saint Petersburg 1
San Francisco 1
Totale 27920
Nome #
Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy 3088
The cachexia score (CASCO) as a tool for staging cachectic cancer patients 1990
Muscle wasting as main evidence of energy impairment in cancer cachexia: future therapeutic approaches 1781
Advances in pharmacologic strategies for cancer cachexia 1621
Open phase II study on efficacy and safety of an oral amino acid functional cluster supplementation in cancer cachexia 1407
The nutritional risk in oncology: a study of 1,453 cancer outpatients 1390
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS) 1351
null 936
null 819
Current medications for cancer cachexia 740
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial 711
Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: Comparison between elderly and non-elderly patient response 685
null 681
Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer 649
Screening the nutritional status in oncology: a preliminary report on 1,000 outpatients 631
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer 589
Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin 2 541
Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters 537
Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy 531
null 529
Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer 489
Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy 419
Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: An evaluation of effectiveness, safety and costs 389
Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexial/cachexia and emesis by peripheral blood mononuclear cells of cancer patients 342
Clinical and immunological evaluation of schizophyllan (SPG) in combination with standard chemotherapy in patients with head and neck squamous cell carcinoma 341
Efficacy, compliance and prognostic significance of a comprehensive geriatric assessment in the geriatric cancer patient = Efficacia, applicabilità e significato prognostico di una valutazione geriatrica multidimensionale nel paziente oncologico anziano 338
Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate 335
Phase II study of induction chemotherapy followed by concomitant chemoradiotherapy in advanced head and neck cancer: clinical outcome, toxicity and organ/function preservation 334
Six-week induction chemotherapy followed by concomitant chemoradiation therapy in stage IV head and neck cancer: a phase II study with organ-sparing purposes 333
A phase II study with antioxidants, both in the diet an supplemented, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia-cachexia and oxidative stress 319
Phase II study of induction chemotherapy followed by concomitant chemoradiotherapy in advanced head and neck cancer: clinical response and organ/function preservation 315
Assessment of the efficacy of two dosages and schedules of human recombinant erythropoietin in the prevention and correction of cisplatin-induced anemia in cancer patients 303
Cisplatin induces serotonin release from human peripheral blood mononuclear cells of cancer patients and methylprednisolone inhibits this effect 303
Neo-adjuvant organ-preserving chemotherapy in the management of locally advanced oral cavity and oropharynx cancer: A tentative quantitative evaluation of organ preservation and clinical response 299
Medroxyprogesterone acetate and megestrol acetate reduce cisplatin-induced serotonin release from human peripheral blood mononuclear cells of cancer patients 299
Relationships betxween Fas expression, activation molecule CD25, and functional activity of tumor-associated lymphomonocytes from neoplastic effusions 293
Medroxyprogesterone acetate reduces the production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients 291
Tumor-associated lymphomonocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokynes 289
Role of proinflammatory cytokines and leptin in cancer-related anorexia/cachexia. Metabolic abnormalities and therapeutic approaches = Ruolo delle citochine infiammatorie e della leptina nell'anoressia/cachessia neoplastica. Aspetti metabolici e terapeutici 284
Neo-adjuvant (primary) organ-preserving chemotherapy in the management of locally advanced laryngeal carcinoma: Larynx preservation and clinical response 239
Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG) 226
Anorexia/Cachexia and oxidative stress in cancer patients = Anoressia/Cachessia e stress ossidativo nei pazienti con cancro 196
Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC 109
An innovative treatment approach for cancer-related anorexia/cachexia and oxidative stress: Background and design of an ongoing, phase III, randomized clinical trial 85
Peripheral blood lymphocyte response to exogenous interleukin 2 by PHA-prestimulated and non-PHA-prestimulated cells in patients with cancer 64
Medroxyprogesterone acetate reduces the In vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients 48
Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin 42
Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy 39
Lack of correlation between defective cell-mediated immunity and levels of secreted or circulating cytokines in a study of 90 cancer patients 33
Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial 33
Preovulatory human follicular fluid in vitro inhibits interleukin (IL)- 1α, IL-2, and production and expression of p55 chain IL-2 receptor of lymphomonocytes 31
Membrane-bound/soluble IL-2 receptor (IL-2R) and levels of IL-1α, IL-2, and IL-6 in the serum and in the PBMC culture supernatants from 17 patients with hematological malignancies 30
[p55 and p75 subunits of the IL 2 receptor, membrane bound and soluble, in peripheral lymphocytes in patients with solid tumors] 28
[The immunological assessment of a combined therapeutic approach (chemo- + radiotherapy +/- surgery) including immunotherapy in neoplasms of the head and neck area at an advanced stage] 26
Membrane-bound and soluble IL-2 receptors (p55 and p75 chains) on peripheral blood mononuclear cells from patients with solid malignancies 23
Immunologic assessment determined by response to IL-2 and immunophenotyping of tumor-infiltrating lymphocytes, of invaded and non invaded lymph nodes and of peripheral blood lymphocytes from twenty-one patients with primary laryngeal cancer 20
Evidence that granulosa cells inhibit interleukin-1α and interleukin-2 production from follicular lymphomonocytes 19
Study of peripheral blood lymphocyte subset distribution and IL-2 receptor (IL-2 R) p55-p75 subunit expression in patients with cancer of different sites 15
Totale 28828
Categoria #
all - tutte 34705
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34705

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/2018404 0000 00 00 000404
2018/20192313 94184513389 244129 14575 7790183190
2019/20207044 47117065154 22701774 855286 215141175468
2020/20218700 3363384472022 18611235 831663 143335369120
2021/20221351 1081049069 15783 6091 120103158208
2022/20232382 186235193178 175292 74478 17015021437
Totale 28828